Cat allergy immunotherapy - Circassia

Drug Profile

Cat allergy immunotherapy - Circassia

Alternative Names: Cat allergen vaccine - Circassia; Cat peptide allergen desensitisation; Cat Synthetic Peptide Immuno-Regulatory Epitopes; Cat-PAD; ToleroMune; ToleroMune Cat

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Circassia
  • Class Allergens; Antiallergics; Cat allergy immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis
  • Discontinued Hypersensitivity

Most Recent Events

  • 30 Jun 2016 Circassia completes the phase III CATALYST trial for Allergic rhinoconjunctivitis in USA, Canada, Belgium, Czech Republic, Germany, Hungary, Poland, Slovakia and Russia (NCT01620762)
  • 01 Dec 2015 Circassia completes a phase II trial in Allergic rhinoconjunctivitis (In children) in Poland and USA (NCT01921257)
  • 11 Aug 2015 Circassia completes enrolment in its phase II trial for Allergic rhinoconjunctivitis (In children) in Poland (NCT01921257)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top